CATALYSTBenzinga • 6d ago
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For MondayAnalysts upgraded SAFE, CNOB, LMT and more.
Why TTRX Stock dropped -3.60% Today — RQD Quant Desk Flash
$10.72 -3.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $10.63
Turn Therapeutics Inc. (TTRX) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $327.3M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $10.63 (-0.84%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TTRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY TTRX SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (26% of score)
FRED Regime × Technicals: 59% of 52W Range • RSI-14 at 43.4 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$12.00-11.9% Next Q
39
Q2 (-2Q)Grade E$10.57-2.7% Next Q
36
Q3 (-1Q)Grade E$10.28+4.3% Next Q
34
CurrentGrade E$10.72-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TTRX Turnaround Squeeze
While TTRX currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.72) and Max Pain ($11.26) forces dealer call-delta covering toward $17.27.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TTRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TTRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TTRX Stock dropped -3.60% Today — RQD Quant Desk Flash
Turn Therapeutics Inc. (TTRX) dropped -3.60% to $10.72, trading at 59% of its 52-week range ($2.57 – $16.45). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 59% of its 52-week range ($2.57 – $16.45) with RSI-14 at 43.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $10.72 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live TTRX Headlines & Catalysts
MARKET WIREBenzinga • 9d ago
This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For FridayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Raymond James
CATALYSTBenzinga • 9d ago
WBB Securities Upgrades Turn Therapeutics to Hold, Maintains Price Target to $10WBB Securities analyst Karen Sterling upgrades Turn Therapeutics (NASDAQ:TTRX) from Sell to Hold and maintains the price target from $10 to $10.
MARKET WIREYahoo • 11d ago
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside ChatWESTLAKE VILLAGE, Calif., October 21, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that B
RISK WATCHYahoo • 11d ago
A CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech…Dr. Robert Redfield and Dr. Stephen Hahn came aboard Turn Therapeutics this year to help the clinical-stage company develop a platform that could one day change how vaccines are delivered.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TTRX)
- ✓Walkthrough of TTRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TTRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +190.51%▼ SUPPORT BREAKDOWN
2026-10-30O $10.45H $10.72L $9.60C $10.72VOL 137.1K
RES: $20.71SUP: $12.02SMA50: $11.72SMA200: $7.00
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TTRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TTRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TTRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TTRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TTRX)
Health Care Rank #919 of 1016
⚔️ PRLD vs TTRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TTRX vs. PRLD, ENTA, ARCT, AVIR)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Turn Therapeutics Inc. (TTRX) ranks #919 by composite RQD confidence (31/100, grade E) and #511 by equity capitalization ($327.3M). Within this direct 5-issuer industry benchmark cohort, TTRX leads on earnings valuation at N/A trailing P/E, while TTRX leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. PRLD currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with TTRX at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TTRX
ACTIVE
Turn Therapeutics Inc. | E | 31/100 | — | — | -28.3% | -3.60% | $327.3M | Benchmark Subject |
| PRLD Prelude Therapeutics Incorporated | D- | 41/100 | — | — | -35.0% | -0.97% | $327.2M | /prld-vs-ttrx → |
| ENTA Enanta Pharmaceuticals Inc. | E | 25/100 | — | — | -35.0% | -3.46% | $324.7M | /enta-vs-ttrx → |
| ARCT Arcturus Therapeutics Holdings Inc. | E | 31/100 | — | — | -35.0% | +0.66% | $345.3M | /arct-vs-ttrx → |
| AVIR Atea Pharmaceuticals Inc. | D- | 40/100 | — | — | -35.0% | +0.94% | $345.7M | /avir-vs-ttrx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002023016In its most recent audited fiscal period (FY2025, filed 2025-12-31), Turn Therapeutics Inc. (TTRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$3.2M, operating cash flow of -$2.6M, and free cash flow of -$2.6M (-88.3% YoY). On the balance sheet, TTRX closed FY2025 with $12.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$3.2M | -$2.6M | -$2.6M | $12.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$1.8M | -$1.4M | -$1.4M | $2.0M | — |
3. TTRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TTRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Turn Therapeutics Inc. (NASDAQ: TTRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $10.72 (-3.60% 1D, market cap $327.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TTRX ranks #919 in composite RQD confidence.
How does TTRX compare to PRLD and ENTA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TTRX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, PRLD (Prelude Therapeutics Incorporated) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $327.2M) and ENTA (Enanta Pharmaceuticals Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $324.7M). Among the 5-stock peer group, TTRX leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TTRX?
Per TTRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023016), Turn Therapeutics Inc. generated $0 in revenue, -$3.2M in net income, and -$2.6M in free cash flow against $12.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TTRX trading relative to its 50-day, 200-day, and 52-week technical levels?
TTRX last traded at $10.72 (-3.60% on volume of 137,714 shares), positioning the stock -8.53% below its 50-day simple moving average ($11.72) and +53.14% above its 200-day simple moving average ($7.00). Across its 52-week range of $2.57 to $16.45, TTRX sits at the 58.7% percentile with a 14-day RSI of 43.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.38 to $12.06).
TTRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TTRX stock moving today?
Why TTRX Stock dropped -3.60% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.